Briefing

Featured article

Intercept winds down NASH programme after FDA pulls plug on Ocaliva

Also in this section

News in Numbers

Latest News

Latest Deals

Project Updates

02/23/2024 21:28:23
  • Home | AI for patients: Hype or Hope
  • Editor's letter
  • Contents
  • Mimotopes Company Insight
  • Mimotopes
  • Briefing
  • News in Numbers
  • Latest News
  • Latest Deals
  • Project Updates
  • Sensified.io
  • In Depth
  • AI for patients: Hype or Hope
  • Readmission on the Horizon: How EU funding can boost British biotech
  • NASH drugs race to cross the finish line
  • Can vouchers incentivise antimicrobial drug discovery in Europe?
  • Q&A: How Big Pharma implements analytics in continuous manufacturing
  • Inflation reduction act boosts biologic VC financing over small molecules
  • B Medical Systems
  • Thematic Take
  • Thematic Take: contents
  • Foreword
  • An introduction to the metaverse
  • A history of the metaverse
  • The impact of the metaverse on the healthcare sector
  • Case studies: the metaverse in the healthcare industry
  • Latest news: metaverse in pharma
  • Apple makes a play to change the health Metaverse arena
  • Why is the healthcare industry hesitant to join the metaverse
  • Deal activity related to the metaverse in the pharmaceutical industry since 2018
  • Metaverse hiring trends in the global pharmaceutical industry since 2020
  • Metaverse patent applications in the global pharmaceutical industry since 2020
  • GlobalData Thematic Intelligence
  • Sponsored Supplements
  • Thermo Fisher Scientific
  • Listings
  • Events
  • Awards
  • Buyer's Guides
  • Next issue
07/06/2023 00:00:00